MONTREAL, Dec. 11, 2012 /CNW/ - Pharmascience Inc. today announced that
it has regained global rights to AEG40826, a best-in-class Phase
1b-ready injectable IAP (inhibitor of apoptosis) inhibitor along with
all back-up and follow-on compounds, including multiple
orally-bioavailable IAP inhibitors, as part of an agreed-upon
termination of its oncology collaboration with Human Genome Sciences
(HGS), which was acquired by GlaxoSmithKline in July 2012.
During the collaboration, HGS conducted Phase 1a trials of AEG40826
(formerly HGS1029) in cancer patients and collaborated with the Aegera
Therapeutics (part of Pharmascience Inc.) research team to identify and
nominate highly differentiated back-up and follow-on IAP inhibitors.
"We are pleased to regain full control of AEG40826, which we believe has
the potential to become the leading IAP inhibitor in view of its
differentiated and highly favourable product profile. We intend to
aggressively explore multiple development and partnering opportunities
simultaneously to establish the best path forward for AEG40826," stated
Dr. David Goodman, Chief Executive Officer, Pharmascience Inc.
"We believe that regaining rights to our AEG40826 IAP inhibitor oncology
program, poised for Phase 1b combination studies, will provide us much
greater flexibility and control in the clinical development of AEG40826
and the back-up and follow-on compounds, as well as the opportunity to
pursue new collaborations. We strongly believe in the therapeutic
potential of our IAP inhibitors in combination with other anti-cancer
agents including chemotherapeutics, TNFR Superfamily agonists and other
biologics for which we have compelling preclinical proof-of-concept. We
intend to validate this hypothesis in Phase 1b and beyond, preferably
with the right partner, but at this time, all options are on the
table," commented Dr. Tristan Booth, Vice President, Clinical and
Innovative Development at Pharmascience.
About the AEG40826/IAP Inhibitor Collaboration and License Agreement
In December 2007, Aegera Therapeutics Inc. (acquired by Pharmascience
Inc. in May 2011) and Human Genome Sciences, Inc. completed a
Collaboration and License Agreement providing HGS with exclusive
worldwide rights (excluding Japan) to develop and commercialize
AEG40826 (HGS1029) and other small molecule IAP inhibitors in oncology.
The collaboration and license agreement was executed the same day
Aegera filed the investigational new drug (IND) application for
AEG40826, which was cleared by the U.S. Food and Drug Administration in
About the AEG40826 IAP Inhibitor Oncology Program
AEG40826 is the most potent small molecule pan-IAP inhibitor in
development. It has demonstrated very promising preclinical activity
across a broad range of cancers, particularly in combination with
chemotherapeutics agents, TNFR Superfamily agonist mAbs and other
In Phase 1a cancer studies, AEG40826 has demonstrated profound and
sustained pharmacodynamic activity on its target(s) and shown a good
tolerability profile. Preclinical evidence along with data from the
Phase 1a studies strongly support the initiation of Phase 1b
In addition to pursuing the development of AEG40826, HGS collaborated
with the Aegera discovery research team over a period of four years to
identify and nominate highly differentiated back-up/follow-on IAP
inhibitors. As a result of a very successful research collaboration and
remarkable work of the Aegera team, multiple back-up/follow-on
development candidates, including several orally bioavailable
compounds, were nominated and are poised for IND-enabling development.
About Pharmascience Inc.
Founded in 1983 in Montreal, where its headquarters remain, privately
held Pharmascience Inc. is Quebec's largest manufacturer of generic
drugs. Through its International Division, its products are exported to
60 countries around the world. It also makes and distributes patented
prescription and over-the-counter treatments through its Pendopharm
division. Aegera Therapeutics is a drug discovery unit of
Pharmascience, which is one of Canada's leading corporate investors in
research and development and employs more than 1,300 people, primarily
in Montreal. Over the past five years, Pharmascience has donated
products with a wholesale value of $23.5 million for overseas
humanitarian use, making it one of the most generous product donors in
the Canadian pharmaceutical industry. www.pharmascience.com.
SOURCE: Pharmascience inc.
For further information:
Mathieu Boudreau, Ph.D.
Director, Business Development & Strategic Planning
(514) 340-9800 ext. 3160
Director of Corporate Affairs and Communications
(514) 340-9800 ext. 3425
Mobile : (514) 979-7577